Upstream Bio Reports Q2 Results, Phase 2 Trials Progressing in Respiratory Diseases

• Upstream Bio on track to report top-line CRSwNP data in Q3 2025 • Completed enrollment in severe asthma trial in June 2025 • First patient dosed in COPD trial in July 2025 • Verekitug targets thymic stromal lymphopoietin receptor in respiratory diseases

Upstream Bio Inc. (NASDAQ: UPB) has reported significant progress in its clinical development pipeline for verekitug, the only monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor in development. The company, which focuses on severe respiratory disorders, has advanced its clinical trials and is on track to report top-line data from its Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 [1].

In June 2025, Upstream Bio completed enrollment in its Phase 2 trial for severe asthma, with top-line data expected in the first quarter of 2026. Additionally, the company dosed its first patient in its Phase 2 trial for chronic obstructive pulmonary disease (COPD) in July 2025, marking the start of development in a third major respiratory indication [1].

Verekitug's unique mechanism of action, targeting the TSLP receptor pathway, has the potential to offer meaningful advantages over existing biologics in the respiratory space. The company's strategic design of clinical trials with endpoints that could support regulatory submissions indicates confidence in the program [1].

Upstream Bio's strong cash position of $393.6 million, which is expected to fund operations through 2027, provides substantial operational flexibility as the company advances multiple clinical programs [1]. The company's increased research and development expenses of $37.9 million reflect the acceleration of clinical activities across multiple programs. While the net loss widened to $40 million from $14.7 million in the prior year period, this increased spending is well-covered by the company's cash position [1].

The upcoming readout from the Phase 2 VIBRANT trial in CRSwNP in Q3 2025 represents a significant near-term inflection point that could validate Upstream Bio's approach to TSLP receptor inhibition. The company's expansion into COPD represents entry into a third major respiratory market with substantial commercial potential [1].

Upstream Bio's strategic focus on severe forms of common respiratory diseases where they see significant potential for clinical impact and commercial opportunity underscores their commitment to addressing unmet needs in the market [1].

References:
[1] https://www.stocktitan.net/news/UPB/upstream-bio-reports-second-quarter-2025-financial-results-and-ctbzbww0v7mz.html